Based on the increase of PD-1 positive CD8+ T cells in tumors in SCD1 inhibitor-treated mice (figure 2B, online supplemental figure 4A, right panel), we evaluated the antitumor effect of a combination of the SCD1 inhibitor and an anti-PD-1 antibody, and synergistic antitumor effects were observed in four tumor models. Here, CD8A is linked to neoplasm.